Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Prioritising nutrient-dense foods will help support overall health and well-being
The brokerage estimates Indias weight-loss market at about $500 million, which could rise to $1 billion with the right pricing, adoption and government incentives. Demand for these weight-loss drugs is also high as Indias 1.4-billion-plus population faces a higher burden of diabetes and cardiovascular ailments, largely due to increasingly sedentary urban lifestyles
Real-world studies have confirmed these results: a 2025 study published in Diabetes, Obesity and Metabolism found tirzepatide was associated with greater weight loss over 6 months than semaglutide in patients without diabetes, consistent with the trial data
A small clinical trial confirmed these findings, showing that exenatide, another GLP-1 agonist, significantly reduced intracranial pressure in patients with idiopathic intracranial hypertension, greatly improving headache symptoms
As shown in Scheme 12
Do women have more adverse drug reactions
US$ 20.76
US$ 24.18
US$ 29.12
US$ 25.99
US$ 28.82
US$ 29.89
US$ 21.07
US$ 23.25
